Modulation of striatal cAMP levels: A key pathway in the treatment of hyperkinetic movement disorders - PubMed
3 months ago
- #Pharmacology
- #Neuroscience
- #Movement Disorders
- Hyperkinetic movement disorders (e.g., dystonia, chorea, myoclonus) impair quality of life.
- Study links striatal cAMP signaling alterations to hyperkinetic disorders, focusing on ADCY5 gene mutations.
- Caffeine shows therapeutic effects in patients with MxMD-ADCY5 and in an Adcy5 R419W mouse model.
- Caffeine improves motor symptoms via adenosine A2A receptor blockade in mice.
- Mutation increases cAMP signaling in striatal neurons, corrected by A2A receptor antagonism.
- Modulating neuronal cAMP levels is a key target for treating hyperkinetic disorders, especially dystonia/dyskinesia.